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Summary. Since more than 20 years elevated homocys-
teine plasma levels have been associated with an elevated
cardiovascular risk. It can be assumed that approx. 5–7% of
the Swiss population suffers from hyperhomocysteinemia.
These people have an odds ratio of 1.7 (95% confidence
interval: 1.5–1.9) to develop a myocardial infarction and
an odds ratio of 2.5 (95% confidence interval 2–3) of
developing a stroke. These significant cardiovascular
endpoints have monetary implications and lead to a loss in
life years. The cost consequences and total life years lost
were determined with an incidence-based epidemiological
model utilizing a Swiss third party payer perspective. We
could demonstrate that hyperhomocysteinemia-related
sequelae (myocardial infarction and stroke) amount to
41.1–110.2 million CHF. In addition it can be estimated
that 6′941–18′478 life years may be lost.
Comparing these data with the total costs for cardiovas-
cular disease in Switzerland of CHF 987 million, we esti-
mate the share of the economic burden of hyperhomocys-
teinemia at approximately 10%. Preventive measures could
thus yield a positive impact on total health care expendi-
ture in the Swiss healthcare system and warrants further
research.
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Introduction
Because the costs in healthcare have been increasing
over proportion in the past decade, economic aspects
of a disease are increasingly becoming important.
Already since many years it has been shown that the
demand for health care services will depend not only
what is technically feasible but also how to deal with
constrained financial resources. For this reason it is
important to allocate health care resources wisely and
to invest in areas where the investment yields the
greatest benefit in terms of health, life years saved
or quality of life. Hence it is important to determine
the burden of disease as a first preparatory step.
Cardiovascular disease is one of the most frequent
causes of death in Switzerland and is also economically
relevant due to the possibilities of extensive and
costly medical interventions. Even coronary heart
disease alone which affects approx. 2% of the Swiss
population, led to expenditures of about 2.1 Billion
CHF in 1993. Of these approximately 47% were direct
costs and 53% were indirect costs [1].
50% of all deaths are caused by atherosclerotic com-
promised vascular structures [2]. Preventive measures
against high blood pressure or high cholesterol lev-
els have been consequently implemented over the last
decade. It has been shown that several factors are re-
sponsible for the development of arteriosclerosis and
its consequences. Albeit intensive research, not all rel-
evant risk factors have been identified as a relevant
co-factor in the development of atherosclerotic disease.
For many years approximately only 50–60% of all cases
of atherosclerosis could be related to a known risk fac-
tor [3].
In the last years a new risk factor has increas-
ingly gained significance. Several studies have shown
that an elevated homocysteine blood level is associated
with an elevated cardiovascular risk. There are only
limited empirical estimates of the economic burden of
homocysteine as a risk-factor. An early estimate was
published by Boushey et al. and suggested this risk fac-
tor is responsible for about 10% of all artherosclerotic
diseases [4]. These findings however have not yet led
to consistent, individual and population-based preven-
tive measures.
In this incidence-based study we investigated the
economic significance of cardiovascular risk associated
with elevated homocysteine levels from the perspec-
tive of the Swiss healthcare system.
Material and Methods
We conducted a cost impact analysis to determine
the cost of hyperhomocysteinemia in Switzerland. To
achieve this we used a simplified healthcare model
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which was limited to the following constraints:
1. Individuals with hyperhomocysteinemia have an el-
evated cardiovascular risk.
2. The most relevant cardiovascular endpoints are my-
ocardial infarction and stroke.
3. The time frame analyzed was 1 year
4. Only direct costs for the sequelae myocardial in-
farction respectively stroke were considered.
By determining the difference of homocysteine-
asscociated risk in patients with and without hyperho-
mocysteinemia in Switzerland we were able to obtain a
rough estimate of the additional number of strokes or
myocardial infarctions, including the monetary conse-
quences, or in the case of death, the extent of life years
lost.
Epidemiologic evidence
Due to inconsequent standardization of measurement
techniques and the non homogenous definition of
hyperhomocysteinemia it was difficult to determine
the exact prevalence. In most available studies it
has been assumed that 5–7% of the population has
an elevated level of hyperhomocysteinemia [5]. We
asssume this prevalence rate could be applicable for
the Swiss situation.
In previously published studies only relative mea-
sures of association (relative risks, odds ratios) have
been reported. Absolute risk reductions have so far
not been determinated for the sequelae of hyperhomo-
cysteinemia. This meant a consequence that the inci-
dence of myocardial infarction and stroke in patients
without the risk factor homocystein is not known. Thus
population-based incidences had to be used to make ap-
propriate assumptions. This approach, however, is not
expected to impact the overall economic results, as we
can assume that clinical sequelae of patients with and
without hyperhomocysteinemia do not differ.
The incidence of myocardial infarction and stroke
were determined by the global health statistics for es-
tablished market economies [6]. Potential life years
lost due to fatal myocardial infarctions and fatal
strokes could be estimated on the basis of the age of
the cardiovascular events, using data from the global
health statistics and using the statistical yearbook of
Switzerland [7].
People with hyperhomocysteinemia have an ele-
vated risk of a myocardial infarction and a stroke. The
value of the relative risk varies considerably in the
prospective case control studies. Stampfer et al. [8].
observed a relative risk of 3.4 (95% confidence interval
1.3–8.8) for myocardial infarction, whereas Folsom and
co-workers [9] did not determine any significant differ-
ence in relative risks.
A meta analysis form Boushey et al. [4] summarized
all studies between 1988 and 1994 on all issues of homo-
cysteinemia. Of all 209 relevant studies, 27 addressed
atherosclerosis and homocysteine and 11 studies were
addressed folic acid and hyperhomocysteinemia blood
levels. These were all considered in a systematic meta-
analysis. The determined odds ratios have been to date
the most reliable values for the determination of risks
and have been used for the present cost impact model.
Following odds ratios were used: myocardial infarc-
tion; odds ratio = 1.7 (95% CI: 1.5–1.9); stroke; odds
ratio = 2.5 (95% CI: 2.0–3.0).
Using these data it is possible to calculate the inci-
dence and mortality rates of myocardial infarction and
stroke in people and individuals with hyperhomocys-
teinemia as follows:
I/MHyperhomocysteinemia = (100′000 × A)/(1 + A)
A= Odds ratio × (I/Mnormal hyperhomocysteinemia/
100′000 − I/Mnormal hyperhomocysteinemia)
I/M = incidence of MI or stroke, resp. mortality rate of
MI or stroke
For the purpose of the sensitivity analysis, the 95%
confidence intervals of the odds ratios were used. Be-
cause the prevalence of hyperhomocysteinemia ranged
between 5 and 7%, the cost impact analysis was based
on these two limits.
We employed two different models:
1. Model 1 used the lower prevalence limit of 5%,
2. Model 2 employed a prevalence of 7%. As a refer-
ence we also used a model with a potential hyperho-
mocysteine prevalence of 0%. Furthermore we as-
sumed that these prevalences were independent of
age and sex. Using data from the Federal Statistical
Office of Switzerland and the prevalence estimates
for hyperhomocysteinemia we were able to deter-
mine the size of the population at risk for Model 1
and Model 2 (Table 1).
Table 1. Esimtated number of individuals with











15–44 15.396 0.770 1.078
45–59 9.911 0.346 0.484
60+ 5.981 0.299 0.419
Females
15–44 15.188 0.759 1.063
45–59 6.887 0.344 0.482
60+ 8.167 0.408 0.572
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Cost data
Cost data for the cardiovascular endpoints myocardial
infarction and stroke were derived from previously
published evidence [10]. All costs were adjusted to
2004 values using the consumer price index for health-
care in Switzerland.
Four data sources were used: H+ statistics for
nationwide hospitalization data, the Swiss drug com-
pendium for legally binding national medication costs
as well as diagnosis related groups from the canton of
Aarau and Basel. The latter were used because Basel
and Aarau have gained early and extensive experience
with prospective payments schemes, e.g. diagnosis re-
lated groups. Ambulatory cost data were derived from
a previously conducted cost structure analysis of my-
ocardial infarctions and strokes [10]. All costing ap-
proaches were described in a Swiss economic analysis
conducted by our group. For the hyperhomocysteine-
mia models the cost of a myocardial infarction were es-
timated at 29′670 CHF and for a stroke 40′942 CHF.
Perspective of the economic analysis
The epidemiological data is specific for Switzerland
in so far as the size of the population was related
to the overall Swiss population. Incidence, mortality
rate, prevalence data and odds ratios were derived
from international studies and were considered gen-
eralisable. Cost structure data (e.g. ambulatory tar-
iffs and charges for medical services) are highly depen-
dent on the individual country. This cost analysis was
performed from the perspective of third party payers.
This analysis is also confined to the total cost of ther-
apy and covers only direct costs of medical interven-
tions. Indirect costs were not taken into consideration.
Results
The incremental costs of hyperhomocysteinemia can
be determined as a difference of the number of my-
ocardial infarctions and strokes between Model 0 and
Model 1 respective Model 2 and the corresponding cost
per case. Because Model 1 and Model 2 contain two dif-
ferent distinct scenarios the results will be discussed
separately.
Results of model 1
Assuming that nobody in Switzerland suffers from
hyperhomocysteinemia, approx. 33′829 myocardial
infarctions occur annually. Of these, approx. 12′069
are fatal. Approx. 20′170 cardiovascular strokes
occur annually of which 7′680 are fatal. In Model 1
approx. 5% of the population has a significant elevated
homocysteine level which leads to an elevated risk
of a myocardial infarction of 33–47%. The risk for a
cerebral vascular insult in this population increases
even 50–66%. Thus it can be estimated in Switzerland
approx. 535–960 nonfatal and 299–536 fatal myocardial
infarctions occur, as well as 617–1′226 nonfatal and
Table 2. Estimated monetary costs of hyperhomocysteine-
mia (Model 1)
Total costs for myocardial infarctions 645.6 million CHF




Total costs for cerebral vascular insults 370.6 million CHF




Attributable cost of hyperhomocyste-
inemia
41.1–78.7 million CHF
Table 3. Estimated number of life years lost (Model 1)
Total number of fatal myocardial
infarctions
12′069 years




Number of fatal myocardial infarctions
due to hyperhomocysteinemia
299–536 years




Number of life years lost due to
hyperhomocysteinemia
6′941–13′198 years
380–757 fatal myocardial infarctions related to hyper-
homocysteinemia. The estimated direct costs resulting
from these events lie between 41.1 and 78.7 million
CHF. Additionally we estimate that between 6′941–
13′198 attributable life years are lost. The results of
model one is displayed in Table 2.
Table (3) displays the calculation of the number of
years lost in Model 1.
Results of model 2
Model 2 assumes a prevalence of hyperhomocysteine-
mia of 7%. From the difference between Model 0 and
Model 2 we can calculate the number of fatal and non
fatal myocardial infarctions respective cerebral vascu-
lar insults due to a hyperhomocysteinemia.
Instead of the annual estimated 535–960 nonfatal
and 299–536 fatal myocardial infarctions as well as the
617–1′226 nonfatal and 380–757 fatal cerebral vascular
insults we observe significantly increased figures. In
Model 2 we can estimated due to hyperhomocysteine-
mia between 750–1′344 nonfatal and 418–740 fatal my-
ocardial infarctions as well as 863–1′716 nonfatal and
533–1′060 fatal cerebral vascular insults.
Due to these figures we can estimate the direct
costs approx. 57.5–110.2 million CHF (as compared
to 41.1–78.7 million CHF). In this model we estimate
that the number of life years lost would be between
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Table 4. Estimated monetary costs of hyperhomocysteinemia
(Model 2)
Total cost of fatal myocardial
infarctions
645.6 million CHF




Cost of cerebral vascular insults
total
370.6 million CHF




Total cost 57.5–110.2 million CHF
Table 5. Number of life years lost (Model 2)
Total number of fatal myocardial
infarctions
12′069 years




Number of fatal myocardial infarctions
due to hyperhomocysteinemia
418–750 years




Number of life years lost due to
hyperhomocysteinemia
9′716–18′478 years
9′716–18′478 (as compared to 6′941–13′198 in Model
1). The results of Model 2 are displayed in Table 4.
Table 5 displays the calculation of the number of years
lost in Model 2
These two models demonstrate that the direct costs
due to hyperhomocysteinemia lie between 41.1 and
110.2 million CHF. In general this would mean that in
Switzerland approx. 4–10% of the direct costs of all my-
ocardial infarctions and cerebral vascular insults can
be attributed to the risk factor homocysteine. With
respect to mortality the results are similar. Between
3% and 9% of all deaths due to myocardial infarctions
and cerebral vascular insults are in direct relationship
to hyperhomocysteinemia. Depending on the baseline
risk the resulting number of life years lost lie between
6′941–18′478 life years lost.
Discussion
Due to the assumptions used in determining the preva-
lence of hyperhomocysteinemia and the relative risks
of the cardiovascular endpoint, these results yield con-
siderable dispersion. Using the lower limits of the con-
fidence interval of the odds ratio and the lower in-
cidence rates the total costs amount to 41.1 million
CHF. In relationship to the 987 million CHF which are
spent annually to treat cardiovascular diseases [1] this
amount does not seem to be of great relevance. How-
ever assuming a prevalence of 7% and an odds ratio of
1.9 for myocardial infarctions as well as an odds ratio
of 3.0 for cerebral vascular insults hyperhomocysteine-
mia for these two endpoints represents a cost propor-
tion of 10% of total cost. These are certainly more cost
relevant.
A similar situation is observed with respect to
life years lost. Our budget impact analysis is very
sensitive with respect to the variability of prevalence
and odds ratio.
Our results contrast and supplement the findings
from Tice et al. [13] performed in the United States.
They performed a cost-effectiveness analysis using the
Coronary Heart Disease Policy Model, a validated,
state-transition model of CHD events in adults aged
35 through 84 years. They concluded that folic acid
and cyanocobalamin supplementation may be cost-
effective among many population subgroups and could
have a major epidemiologic benefit for primary and
secondary prevention of CHD if ongoing clinical tri-
als confirm that homocysteine-lowering therapy de-
creases CHD event rates.
The initially posted question on the cost relevance
of hyperhomocysteinemia in Switzerland is thus only
clarified from a limited perspective. However these
data give a first impression on the range of costs which
are related to the consequences of hyperhomocysteine-
mia. These can be used as a basis for further research
in the area of individual and population based preven-
tive strategies.
Our model has several limitations: The incidence
of myocardial infarction in cerebral vascular insults in
patients without hyperhomocysteinemia is not known.
For these reasons we had to use secondary published,
aggregated data. Thus the incremental cost of hyper-
homocysteinemia might lead to a slight overestimation
of the true cost.
The prevalence of hyperhomocysteinemia is insofar
questionable as there are not yet consistent and pre-
cise definitions. In most studies there is not a solid up-
per limit. Usually authors tend to use the upper 95%
confidence interval limit as a reference value for hy-
perhomocysteinemia.
Another limitation is that our model did not include
data from two clinical trials which were published sub-
sequent to our model development [11,12]. The two
controlled total homocysteine (tHcy)-lowering treat-
ment studies have been conducted in the United States
and Canada among patients with coronary artery dis-
ease who have been chronically exposed to a back-
ground of folic acid-fortified cereal grain flour since
1999. These trials were however small and the effect
sizes were well in the realm of the values used in our
models.
Lastly, in our model, we only analyzed two cardio-
vascular endpoints: myocardial infarction and cerebral
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vascular insults. Although these are the most fre-
quent cardiovascular sequelae they do not represent
the totality of hyperhomocysteinemia in used costs.
Unfortunately, we did not have health economic data
on congestive heart failure, which represents another
clinically relevant endpoint. Thus in the present study
we give an underestimate of the true costs. In the
future, however, a more complete burden of disease
study is warranted, which should include a wider
range of clinical and economic sequelae, perhaps even
indirect costs.
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